• Facilities
    • Cork, Ireland
    • Cramlington, UK
    • Deeside, UK
    • Newcastle Biosphere, UK
    • North Carolina, US
    • Wisconsin, US
  • Sustainability
    • Environmental sustainability
  • Molecule Lifecycle
    • Discovery
    • Preclinical
    • Phase One
    • Phase Two
    • Phase Three
    • Launch
  • About Us
    • Our Heritage
    • Vision and Values
    • HSE
    • Quality and Regulatory
    • Technology and Innovation Programme
    • PDMO
    • Executive Team
    • Community
  • Careers Hub
    • Our Vacancies
    • Life at Sterling
    • STEM
    • Early Career Paths at Sterling
    • Professional Career Paths at Sterling
    • Meet our People
    • Our Locations
  • News and Events
    • News
    • Events
  • Contact
Sterling Pharma Solutions Logo
Sterling Pharma Solutions Logo
✕
  • Dedicated Scientists
    • Full Time Equivalent (FTE)
    • Extended Benchâ„¢
  • Chemistry Services
    • Drug Discovery
    • Early Scale Up
    • Analytical Services
    • Radiolabelling
  • Small Molecules
    • Small Molecule Services
      • API Development
      • API Manufacturing
      • CMC Services
      • Solid State Chemistry
      • Milling/Micronisation
    • Small Molecule Technologies
      • Hazard Evaluation
      • Chiral Chemistry
      • Hazardous Chemistry
      • Diazomethane
      • Continuous | Flow
      • Biocatalysis
      • High Potency APIs
      • Controlled Substances
  • Peptides
  • ADCs
    • ADC Development
    • ADC Analytical Services
    • Mass Spectrometry
    • ADC Clinical Manufacturing
    • Linker Payloads
  • Knowledge Hub
  • Home
  • Dedicated Scientists
    • Full Time Equivalent (FTE)
    • Extended Benchâ„¢
  • Chemistry Services
    • Drug Discovery
    • Early Scale Up
    • Analytical Services
    • Radiolabelling
  • Small Molecules
    • Small Molecule Services
      • API Development
      • API Manufacturing
      • CMC Services
      • Solid State Chemistry
      • Milling/Micronisation
    • Small Molecule Technologies
      • Hazard Evaluation
      • Chiral Chemistry
      • Hazardous Chemistry
      • Diazomethane
      • Continuous | Flow
      • Biocatalysis
      • High Potency APIs
      • Controlled Substances
  • Peptides
  • ADCs
    • ADC Development
    • ADC Analytical Services
    • Mass Spectrometry
    • ADC Clinical Manufacturing
    • Linker Payloads
  • Molecule Lifecycle
  • Knowledge Hub
  • About Us
    • Our Heritage
    • HSE
    • Quality and Regulatory
    • Technology and Innovation Programme
    • PDMO
    • Executive Team
    • Community
  • Facilities
  • Sustainability
  • Careers Hub
    • Our Vacancies
    • Life at Sterling
    • STEM
    • Early Career Paths at Sterling
    • Professional Career Paths at Sterling
    • Vision and Values
    • Meet our People
    • Our Locations
  • News and Events
  • Contact
Home - Knowledge Hub - Drug Discovery - Making sense of early phase research and development

Making sense of early phase research and development

Making Sense of1 min read 23rd Aug 2022
Share via email Share via LinkedIn

Reviewed by:

Emma Rhodes - Head of New Product Introduction

Emma Rhodes

PhD | Head of New Product Introduction

As the pharmaceutical industry continuously evolves, organisations increasingly aim to ensure that their API is ready for scale-up early in the development process. Click download to find out more.

Download resource
Share via email Share via LinkedIn
Whitepaper7 min read
Scaling ring-closing metathesis in API development: Challenges and success factors Read more
ADC manufacturing facilities at Sterling Pharma Solutions' Deeside, Wales facilities
Blog7 min read
Top 5 considerations in ADC clinical manufacturing Read more
HPAPI capabilities at Germantown, Wisconsin HPAPI
One pager5 min read
HPAPI development and manufacture: From medicinal chemistry to process chemistry Read more
Scott Bruce - Head of Production People
Spotlight5 min read
Scientist Snapshot | Scott Bruce, Head of Production Read more
Infographic1 min read
Solid form development: Evaluating salt hits against free API to achieve an optimal target form Read more
Sterling scientist in the lab using HPLCs
Blog6 min read
Deuteration in API development: Synthetic, analytical and engineering considerations Read more

Sign up for updates

Be the first to see the latest articles and updates from industry leaders, delivered straight to your inbox

This field is for validation purposes and should be left unchanged.
Name(Required)
This field is hidden when viewing the form
Please click here for our privacy policy
Sterling Pharma Solutions Footer LogoService. Passion. Science.
linkedin iconfacebook iconyoutube icon
Enquire now
  • Privacy Policy
  • Cookie Policy
  • Manage Cookies
  • Website Terms and Conditions
  • Gender Pay Gap
  • Modern Slavery Policy

PDMO® is registered in the U.S. Patent and Trademark Office.

PDMO® is a registered trademark of Sterling Pharma Solutions Limited (EUIPO and UKIPO). All rights reserved.

Sterling Pharma Solutions Limited. Registration number: 05712796. Registered office address: Dudley Lane, Dudley, Cramlington, NE23 7QG, United Kingdom. Registered in England.
VAT number: GB320549229